Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Receivables (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Receivables for 3 consecutive years, with $12.7 million as the latest value for Q1 2026.

  • Quarterly Receivables rose 60.29% to $12.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Jan 2026, up 60.29% year-over-year, with the annual reading at $8.1 million for FY2025, 304.45% up from the prior year.
  • Receivables for Q1 2026 was $12.7 million at Kestra Medical Technologies, up from $10.4 million in the prior quarter.
  • The five-year high for Receivables was $12.7 million in Q1 2026, with the low at $2.0 million in Q2 2024.
  • Average Receivables over 3 years is $8.4 million, with a median of $8.7 million recorded in 2025.
  • The sharpest move saw Receivables surged 304.45% in 2025, then soared 60.29% in 2026.
  • Over 3 years, Receivables stood at $2.0 million in 2024, then surged by 421.17% to $10.4 million in 2025, then rose by 22.05% to $12.7 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $12.7 million, $10.4 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.